Testosterone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and SMC (Scotland) recommended or restricted testosterone, while CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 22.2 years separate the first record, 4 Nov 2003 at SMC (Scotland), from the most recent, 23 Feb 2026 at PHARMAC (New Zealand).
PHARMAC (New Zealand) changed its position: not recommended on 25 Aug 2020, restricted by 23 Feb 2026, after a resubmission.
No assessment is on file from TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 15 records date from 2023 or later.
6 distinct indication wordings are recorded for testosterone by the agencies that label one in English (AWMSG, PBAC and SMC).
6 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess testosterone, on 4 Nov 2003; CIPM (Spain) did not open a file until 19 Jun 2024 — an unusually long tail of 20.6 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 11 years in total.
3 of the 6 agencies here assessed testosterone more than once, PBAC (Australia) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for testosterone.
The full ledger for testosterone reads 7 recommended, 4 not recommended, 3 restricted and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Hypoactive sexual desire dysfunction (HSDD) | Not Recommended | source |
| CIPM (Spain) | 19 Jun 2024 | Indicaciones terapéuticas autorizadas: Terapia de sustitución de testosterona en el hipogonadismo masculino, cuando el d… | not financed by the SNS · art. 92 d, e | source |
| PHARMAC (New Zealand) | 15 Aug 2022 | Transdermal hormone replacement | PTAC advice: High · decision reached | source |
| SMC (Scotland) | 8 Apr 2019 | For replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. | accepted (restricted) | source |
| AWMSG (Wales) | 30 Nov 2018 | Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical featu… | outside AWMSG criteria | source |
10 further decisions for testosterone, across 4 agencies, are not shown here. They include the most recent record on file, 23 Feb 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- infliximab — also decided by PHARMAC in 2026Q1
- atezolizumab — also decided by PHARMAC in 2026Q1
- ipilimumab / nivolumab — also decided by PHARMAC in 2026Q1
- nivolumab — also decided by PHARMAC in 2026Q1
- vedolizumab — also decided by PHARMAC in 2026Q1
- glofitamab — also decided by PHARMAC in 2026Q1
Coverage: 15 decisions for testosterone from 6 agencies, 2003 to 2026. Data to 7 Sep 2026. ATC class G03B — Sex hormones and modulators. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.